Chemours Co (CC) — SEC Filings

Latest SEC filings for Chemours Co (CC), explained in plain English.

Sentiment Overview: 1 bullish, 1 bearish, 47 neutral, 1 mixed

Recent Filings (50)

• Chemours Director Exercises Stock Options — 4 · 2026-04-01T17:00:12-04:00 [neutral] Risk: low
  On March 31, 2026, Courtney Mather, a director at The Chemours Company, acquired 1,000 shares of common stock through the exercise of options. The transaction w
• Chemours Swings to Profit in Q3, Operating Expenses Tumble — 10-Q · 2025-11-06T00:00:00.000Z [mixed] Risk: medium
  Chemours Co (CC) reported a significant turnaround in net income for the three months ended September 30, 2025, achieving a net income of $60 million, a substan
• 8-K Filing — 8-K · 2025-10-31T00:00:00.000Z [neutral]
• Chemours Co. Enters Material Definitive Agreement — 8-K · 2025-10-16T00:00:00.000Z [neutral] Risk: medium
  On October 13, 2025, The Chemours Company entered into a material definitive agreement. This agreement also created a direct financial obligation for the compan
• Chemours Files 8-K: Other Events Notification — 8-K · 2025-09-03T00:00:00.000Z [neutral] Risk: low
  On September 2, 2025, The Chemours Company filed an 8-K report detailing "Other Events." The filing does not contain specific financial figures or new material
• Chemours Announces Board and Executive Changes — 8-K · 2025-08-29T00:00:00.000Z [neutral] Risk: medium
  On August 29, 2025, The Chemours Company filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates the de
• Chemours Q2 Sales Dip 10% Amidst Rising Environmental Liabilities — 10-Q · 2025-08-05T00:00:00.000Z [bearish] Risk: high
  Chemours Co reported a net sales decrease of 10% to $1.6 billion for the three months ended June 30, 2025, compared to $1.78 billion in the prior-year period. N
• Chemours Files 8-K: Material Agreement & Financials — 8-K · 2025-08-04T00:00:00.000Z [neutral] Risk: low
  On August 3, 2025, The Chemours Company entered into a Material Definitive Agreement related to its financial statements and exhibits. The company, incorporated
• Chemours Files 10-Q: Focus on PFAS and Restructuring — 10-Q · 2025-05-06T00:00:00.000Z [neutral] Risk: medium
  Chemours Co. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates. Key areas of focus include r
• Chemours Co. Files 8-K on Shareholder Vote Matters — 8-K · 2025-04-24T00:00:00.000Z [neutral] Risk: low
  On April 22, 2025, The Chemours Company filed an 8-K report detailing a submission of matters to a vote of its security holders. The filing, made on April 24, 2
• Chemours Files Proxy Statement for Shareholder Meeting — DEFA14A · 2025-04-15T00:00:00.000Z [neutral] Risk: low
  The Chemours Company filed a Definitive Proxy Statement (DEFA14A) on April 15, 2025, for its annual shareholder meeting. The filing outlines the company's gover
• Chemours Files Proxy Statement for Annual Shareholder Meeting — DEFA14A · 2025-04-14T00:00:00.000Z [neutral] Risk: low
  The Chemours Company (Chemours) has filed a Definitive Proxy Statement (DEFA14A) for its Annual Meeting of Shareholders. The filing indicates that the company i
• Chemours Files Proxy Statement for Shareholder Meeting — DEFA14A · 2025-04-07T00:00:00.000Z [neutral] Risk: low
  The Chemours Company filed a Definitive Proxy Statement (DEFA14A) on April 7, 2025, for its annual shareholder meeting. The filing outlines the company's govern
• Chemours Files Proxy Statement for Shareholder Meeting — DEFA14A · 2025-04-01T00:00:00.000Z [neutral] Risk: low
  The Chemours Company (Chemours) filed a Definitive Proxy Statement (DEFA14A) on April 1, 2025, for its annual shareholder meeting. The filing outlines the agend
• Chemours Files 8-K Report — 8-K · 2025-03-31T00:00:00.000Z [neutral] Risk: low
  On March 28, 2025, The Chemours Company filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," with no speci
• Chemours Co. Files 2025 Proxy Statement — DEF 14A · 2025-03-20T00:00:00.000Z [neutral] Risk: low
  Chemours Co. filed its definitive proxy statement (DEF 14A) on March 20, 2025, for its annual meeting on April 22, 2025. The filing outlines the company's gover
• Chemours Announces Board Changes — 8-K · 2025-03-10T00:00:00.000Z [neutral] Risk: low
  The Chemours Company announced on March 9, 2025, a change in its board of directors. Specifically, it reported the departure of director Mark P. Vergnani and th
• Chemours Files 2024 10-K, Details Financials and Debt — 10-K · 2025-02-18T00:00:00.000Z [neutral] Risk: medium
  Chemours Co. filed its 2024 10-K on February 18, 2025, detailing its financial performance and operations for the fiscal year ending December 31, 2024. The repo
• Chemours Announces Executive Departures and Board Changes — 8-K · 2025-02-11T00:00:00.000Z [neutral] Risk: medium
  On February 10, 2025, The Chemours Company announced changes in its executive leadership, including the departure of its Chief Financial Officer, Jonathan F. Se
• Chemours Announces Board Changes and Executive Compensation Updates — 8-K · 2025-01-07T00:00:00.000Z [neutral] Risk: low
  On January 3, 2025, The Chemours Company filed an 8-K report detailing changes in its board of directors and executive compensation. Specifically, the company a
• Chemours Co. Files 8-K with Financial Obligations — 8-K · 2024-12-13T00:00:00.000Z [neutral] Risk: medium
  On December 13, 2024, The Chemours Company entered into a material definitive agreement related to financial obligations. This filing also includes Regulation F
• Chemours Files 8-K/A Amendment — 8-K/A · 2024-12-02T00:00:00.000Z [neutral] Risk: low
  The Chemours Company filed an 8-K/A on December 2, 2024, to amend a previous filing. The amendment pertains to financial statements and exhibits, with the earli
• Chemours Co. Files 8-K: Material Agreement & Financial Obligations — 8-K · 2024-11-29T00:00:00.000Z [neutral] Risk: medium
  On November 29, 2024, The Chemours Company entered into a material definitive agreement. This filing also indicates the creation of a direct financial obligatio
• Chemours Co. Files 8-K: Material Agreement & Financial Obligation — 8-K · 2024-11-27T00:00:00.000Z [neutral] Risk: medium
  On November 27, 2024, The Chemours Company (Chemours) entered into a material definitive agreement. This filing also indicates the creation of a direct financia
• Chemours Files 8-K Report — 8-K · 2024-11-13T00:00:00.000Z [neutral] Risk: low
  On November 13, 2024, The Chemours Company filed an 8-K report detailing an "Other Event." The filing does not contain specific financial figures or significant
• SC 13G/A Filing — SC 13G/A · 2024-11-12T00:00:00.000Z [neutral]
• Chemours Co. Files Q3 2024 10-Q — 10-Q · 2024-11-04T00:00:00.000Z [neutral] Risk: medium
  Chemours Co. filed its 10-Q for the period ending September 30, 2024. The company reported its financial performance and condition, including details on its deb
• 8-K Filing — 8-K · 2024-08-14T00:00:00.000Z [neutral]
• Chemours Co. Files 10-Q for Q2 2024 — 10-Q · 2024-08-01T00:00:00.000Z [neutral] Risk: medium
  Chemours Co. filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operational updates. Key financial figures and bus
• Chemours Names Interim CEO and CFO Amid Leadership Changes — 8-K · 2024-07-25T00:00:00.000Z [neutral] Risk: medium
  The Chemours Company announced on July 23, 2024, changes in its executive team. Mark P. Vergnano is stepping down as Chief Executive Officer, and Denise L. Dign
• Chemours Appoints New Directors, Adjusts Executive Compensation — 8-K · 2024-06-13T00:00:00.000Z [neutral] Risk: medium
  On June 12, 2024, The Chemours Company announced changes to its Board of Directors. Mark P. Vergnano and Dawn R. Riley have been appointed to the Board, effecti
• Chemours Announces Board and Executive Changes — 8-K · 2024-06-05T00:00:00.000Z [neutral] Risk: medium
  On May 31, 2024, The Chemours Company filed an 8-K report detailing changes in its board of directors and executive compensation. The filing includes the depart
• Chemours Files 8-K: Other Events & Financials — 8-K · 2024-06-03T00:00:00.000Z [neutral] Risk: low
  On May 31, 2024, The Chemours Company filed an 8-K report detailing "Other Events" and "Financial Statements and Exhibits." The filing does not disclose specifi
• Chemours Reports Shareholder Vote Results — 8-K · 2024-05-23T00:00:00.000Z [neutral] Risk: low
  On May 21, 2024, The Chemours Company filed an 8-K to report on matters submitted to a vote of its security holders. The filing details the outcomes of a shareh
• Chemours Files Definitive Proxy Materials — DEFA14A · 2024-05-09T00:00:00.000Z [neutral] Risk: low
  The Chemours Company filed a Definitive Additional Materials (DEFA14A) proxy statement on May 9, 2024. This filing is related to the company's proxy materials a
• Chemours Co. Files Q1 2024 10-Q — 10-Q · 2024-04-30T00:00:00.000Z [neutral] Risk: medium
  Chemours Co. filed its 10-Q for the period ending March 31, 2024. The company reported financial results and provided updates on its business operations. Key fi
• Chemours Elects New Directors, Discloses Executive Pay — 8-K · 2024-04-25T00:00:00.000Z [neutral] Risk: low
  On April 23, 2024, The Chemours Company announced changes to its Board of Directors, including the election of two new independent directors, Ms. Sarah E. Colem
• Chemours Files 2024 Proxy Statement — DEF 14A · 2024-04-11T00:00:00.000Z [neutral] Risk: medium
  The Chemours Company filed its DEF 14A proxy statement on April 11, 2024, for its annual meeting on May 21, 2024. This filing outlines the company's governance,
• Chemours Files 8-K for Financial Statements and Exhibits — 8-K · 2024-03-29T00:00:00.000Z [neutral] Risk: low
  On March 28, 2024, The Chemours Company filed an 8-K to disclose information regarding its financial statements and exhibits. This filing is a routine update an
• Chemours Files 8-K on Financials — 8-K · 2024-03-28T00:00:00.000Z [neutral] Risk: low
  On March 27, 2024, The Chemours Company filed an 8-K report detailing its financial results and condition. The filing includes financial statements and exhibits
• Chemours Co. Files 2023 10-K — 10-K · 2024-03-27T00:00:00.000Z [neutral] Risk: medium
  Chemours Co. filed its 2023 10-K on March 27, 2024, reporting on its fiscal year ending December 31, 2023. The company, headquartered in Wilmington, DE, operate
• Chemours Co Files 8-K with Financial Exhibits — 8-K · 2024-03-26T00:00:00.000Z [neutral] Risk: low
  On March 26, 2024, The Chemours Company filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating updates or disclosures
• Chemours Adds Directors, Updates Executive Pay — 8-K · 2024-03-25T00:00:00.000Z [neutral] Risk: low
  On March 22, 2024, The Chemours Company filed an 8-K report detailing changes in its board of directors and executive compensation. Specifically, the company an
• Chemours Co. Files 8-K on Listing Rule Compliance — 8-K · 2024-03-19T00:00:00.000Z [neutral] Risk: medium
  On March 18, 2024, The Chemours Company filed an 8-K report to address a notice of delisting or failure to satisfy a continued listing rule. The company is also
• Chemours Files 8-K for Regulation FD Disclosure — 8-K · 2024-03-07T00:00:00.000Z [neutral] Risk: low
  On March 6, 2024, The Chemours Company filed an 8-K to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain spec
• Chemours Co Reports Executive Changes and Compensation Updates — 8-K · 2024-02-29T00:00:00.000Z [neutral] Risk: medium
  The Chemours Company filed an 8-K on February 28, 2024, reporting on the departure of directors or certain officers, election of directors, appointment of certa
• Chemours Reports Executive Changes and Compensation Arrangements — 8-K · 2024-02-16T00:00:00.000Z [neutral] Risk: medium
  The Chemours Company filed an 8-K on February 16, 2024, reporting an event that occurred on February 12, 2024. The filing pertains to Item 5.02, "Departure of D
• SC 13G/A Filing — SC 13G/A · 2024-02-13T00:00:00.000Z [neutral]
• Chemours Files Standard 8-K on February 13, 2024 — 8-K · 2024-02-13T00:00:00.000Z [neutral] Risk: low
  The Chemours Company filed a Form 8-K with the SEC on February 13, 2024. This filing, identified by accession number 0000950170-24-014589, reports on 'Other Eve
• FMR LLC & Abigail Johnson Boost Chemours Co. Stake to 11.077% — SC 13G/A · 2024-02-09T00:00:00.000Z [bullish] Risk: low
  FMR LLC, a major investment firm, and its CEO, Abigail P. Johnson, have updated their ownership stake in Chemours Co. As of December 31, 2023, they collectively